Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

Dow Jones

May 30, 2025

0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. "We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions," Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 30, 2025 02:32 ET (06:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2539210008"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539210008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539210008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539210008","market":"fut","top_or_hot":-1,"title":"Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 30, 2025 02:32 ET (06:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-30 14:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 30, 2025 02:32 ET (06:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1804176565.USD","symbol_name":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2539210008","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539210008","pubTimestamp":1748586720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4198":"医疗保健用品","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4534":"瑞士信贷持仓","ALC":"Alcon Inc"},"translate_title":"爱尔康自上市以来首次获得FDA批准是积极的，但在意料之中——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9},"content_text":"0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 02:32 ET (06:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}